
美国当局指控一家加拿大医疗公司的高管涉嫌走私、共谋及进口标签错误药品供美国患者使用。
Key Points - U.S. authorities have charged an executive of a Canadian healthcare company with smuggling, conspiracy and importing a misbranded drug for patient use in the United States.
美国食品药品监督管理局(FDA)针对 CANARX 的案件部分建立在替代资助计划(AFP)市场上一位同行 CEO 提供的信息之上。
- The Food and Drug Administration's case against CANARX was built in part on information provided by a peer CEO in the alternative funding program market.
CANARX 曾出现在 CNBC 对蓬勃发展的 AFP 行业的调查中,该行业承诺降低美国人的处方药成本,但可能违反美国进口法律。
- CANARX was featured in a CNBC investigation into the booming AFP industry, which promises to lower prescription drug costs for Americans but could be in violation of U.S. import laws.
该公司总法律顾问称 CANARX 合法经营,且该高管否认指控。
- The company's general counsel says CANARX has operated legally and that the executive denies the charges.
立即观看 视频 31:20 31:20 高昂药价如何助长联邦当局所谓的非法进口计划针对一起涉嫌非法处方药运营及其两名核心负责人的联邦案件于本月早些时候启动,案件中一名值得注意的线人浮出水面:一家同行公司的 CEO,当局称该公司实施了相同的进口违规行为。
watch nowVIDEO31:2031:20How high drug costs fueled what feds call an illegal import scheme The federal case against an alleged illegal prescription drug operation and its two top leaders earlier this month features a notable informant: the CEO of a peer company that authorities say was committing the same import violations.
加拿大医疗公司 CANARX 的财务主管兼董事 John Thomas Howard 于 11 月 8 日在连接底特律与加拿大的隧道中被捕,面临走私、共谋及进口标签错误药品供美国患者使用的指控。法庭记录显示,该公司总裁、他的兄弟 Bob Howard 因类似指控被通缉,截至上周仍在逃。
John Thomas Howard, treasurer and director of a Canadian healthcare company called CANARX, was arrested in the tunnel connecting Detroit and Canada on Nov. 8 and charged with smuggling, conspiracy and importing a misbranded drug for patient use in the United States. His brother and the president of the company, Bob Howard, is wanted on similar charges and was still being sought as of last week, according to court records.
这些指控标志着美国当局首次对替代资助计划(AFP)行业公司提起刑事诉讼。这类计划承诺降低或消除美国人高昂的处方药费用。
The charges mark the first criminal case by U.S. authorities against a company that's part of a cottage industry known as alternative funding programs, or AFPs, that promise to lower or eliminate high prescription drug costs for Americans.
美国食品药品监督管理局和国土安全部表示,这些价格更低的药物通常来自国际市场,这种商业模式属于非法,且可能危及患者健康。
The cheaper medications are typically sourced from international markets, a business model that the Food and Drug Administration and Department of Homeland Security say is illegal and can put patients' health at risk.
核心问题在于面向外国市场的药品缺乏监管,以及在某些情况下存在假冒产品的风险。虽然AFP(美国外国药房)通常主张根据美国法律,个人为自用进口药品是被允许的,但当局认为这些运营行为已超出法律许可范围。
At issue is the unregulated nature of drugs intended for foreign markets and, in some cases, the risk of counterfeit products. And while AFPs generally argue that the importation of medication is allowable under U.S. law by individuals for personal use, authorities contend the operations go too far.
总部位于安大略省温莎市的CANARX成立于2002年,曾在CNBC对蓬勃发展的AFP行业的调查报道中被提及。
CANARX, based in Windsor, Ontario, was established in 2002 and was featured in a CNBC investigation into the booming AFP industry.
CANARX总法律顾问约瑟夫·莫里斯去年告诉CNBC,该公司合法经营,并对其提供的处方药安全性充满信心。上周,莫里斯告诉CNBC,霍华德兄弟“否认所有指控,将进行强有力的辩护,并预期在法庭上获得平反。”
Joseph Morris, general counsel for CANARX, told CNBC last year that the business was operating legally and was confident in the safety of the prescriptions it provided. Last week, Morris told CNBC that the Howard brothers "deny all the charges against them, will defend vigorously, and expect to be vindicated in court."
CEO化身线人FDA针对CANARX的案件始于一条关于名为ScriptSourcing的类似医疗运营的举报线索。该线索详细记录在一份35页的宣誓书中——日期为10月29日,上周解封——由FDA刑事调查办公室特别探员达斯汀·多布斯撰写。
CEO turned informant The FDA's case against CANARX started with a tip about a similar healthcare operation called ScriptSourcing. It is detailed in a 35-page affidavit — dated Oct. 29 and unsealed last week — written by Dustin Dobbs, special agent with the FDA's Office of Criminal Investigations.
总部位于佛罗里达州博尼塔斯普林斯的ScriptSourcing将其国际处方药项目推销给自筹资金的雇主健康计划。根据公司网站介绍,创始人兼CEO加里·贝克尔是“拥有30多年经验的健康保险和风险管理顾问”。
Based in Bonita Springs, Florida, ScriptSourcing marketed its international prescription program to self-funded employer health plans. Founder and CEO Gary Becker was described on the company's website as a "health insurance and risk management consultant for more than 30 years."
根据宣誓书,ScriptSourcing至少自2022年起就因潜在的药品进口违规行为进入FDA视野。2025年8月,多布斯假装成对AFP业务感兴趣的人,给ScriptSourcing发送电子邮件,询问该公司是否符合FDA合规要求。
ScriptSourcing had been on the FDA's radar since at least 2022 for potential drug import violations, according to the affidavit. In August 2025, Dobbs, posing as someone interested in the AFP business, emailed ScriptSourcing and asked if the company was FDA-compliant.
一名ScriptSourcing员工在回复多布斯时表示,公司符合FDA合规要求,拥有2000多种品牌特种药物,并与3000多个自筹资金的健康计划合作。
A ScriptSourcing employee in responses to Dobbs said the company was FDA-compliant and that it had more than 2,000 name brand specialty medications and worked with more than 3,000 self-funded health plans.
然而,根据多布斯的宣誓书,同年该机构获悉了两起据称涉及 ScriptSourcing 国际药品进口项目药物伤害患者的事件。一名患者在使用该公司通过一家加拿大药房采购的标签错误的 Mounjaro(替西帕肽)后,因小肠梗阻住院;另一名患者据称在服用假冒药物后严重受伤。
However, that same year, the agency learned of two alleged incidents in which medications from ScriptSourcing's international drug import program had harmed patients, according to Dobbs' affidavit. One patient had been hospitalized due to a small bowel obstruction after she used misbranded Mounjaro sourced by the company via a Canadian pharmacy, and another was allegedly seriously injured after receiving a counterfeit medication.
面对 FDA 的审查,ScriptSourcing 首席执行官贝克尔反咬 CANARX 的霍华德兄弟一口。
Facing scrutiny from the FDA, ScriptSourcing CEO Becker turned on the Howard brothers of CANARX.
多布斯写道,到 2026 年 5 月,贝克尔已成为政府针对这家加拿大公司调查中的合作证人。根据宣誓书,贝克尔告诉 FDA,他曾与 CANARX 在药品进口方面有业务往来,且该公司曾给他提供了一份关于如何运作的“路线图”。
By May 2026, Becker had become a cooperating witness for the government in its investigation into the Canadian firm, Dobbs wrote. Becker told the FDA that he had done business with CANARX on drug importation and that the company had given him a "road map" on how to operate, according to the affidavit.
宣誓书称,ScriptSourcing 向 FDA 提供了一份 2021 年至 2026 年期间与 CANARX 资金往来的电子表格。表显示约有 16,549 份处方药被配发。
ScriptSourcing provided the FDA with a spreadsheet of financial transactions with CANARX between 2021 and 2026. It showed approximately 16,549 prescription drugs have been dispensed, the affidavit said.
随后,在 2026 年 6 月至 7 月的几通录音电话中,贝克尔与霍华德兄弟讨论了海外药品进口事宜。
Then, in several recorded phone calls between June and July 2026, Becker discussed the foreign importations with the Howard brothers.
多布斯在宣誓书中写道:“这些电话录音显示,约翰·霍华德知晓从加拿大向美国进口药品的渠道,并试图将其改造以适应 CANARX 的非法药品进口项目。这些电话录音还显示,约翰·霍华德和鲍勃·霍华德知晓这些药品不允许合法进入美国。”
The phone calls "show that John Howard was aware of the routes for importation of drugs from Canada into the United States and has tried to mold them to fit [CANARX's] illegal drug importation program," Dobbs wrote in the affidavit. "These phone calls also show that John Howard and Bob Howard were aware that these drugs were not allowed to enter into the United States legally."
在提供信息当时,CANARX 正在运送或准备发运的货物中,有一个包裹装有 Neupro(罗替戈汀),这是一种受 FDA 监管、用于治疗帕金森病和不宁腿综合征的药物。FDA 未回应 CNBC 就宣誓书细节提出的置评请求。
Among the shipments en route or being prepared by CANARX at the time the information was provided was a package that contained Neupro, an FDA-regulated drug for the treatment of Parkinson's disease and restless legs syndrome. The FDA did not respond to a request for comment from CNBC on the details in the affidavit.
加里·贝克尔的律师乔治·卡拉韦托斯在接受CNBC联系时拒绝置评,但于周一确认ScriptSourcing已不再营业。
Gary Becker's attorney, George Karavetsos, declined to comment when reached by CNBC, but confirmed on Monday that ScriptSourcing was no longer in business. ## AFPs' position
AFP的立场AFP的商业模式是吉利德科学公司于2024年12月提起的一起民事诉讼的核心,该诉讼指控包括CANARX在内的几家公司非法进口其艾滋病药物Biktarvy。CANARX未对吉利德的指控作出回应。
The AFP business model was at the center of a civil lawsuit originally filed by Gilead Sciences in December 2024 that alleged several companies, including CANARX, illegally imported its HIV drug Biktarvy. CANARX has not responded to Gilead's allegations.
吉利德上周在给CNBC的一份声明中,针对霍华德兄弟面临的指控表示,它“欢迎政府努力追究那些其行为可能使患者面临风险之人的责任。”
Gilead said in a statement to CNBC last week in response to charges against the Howard brothers that it "welcomed the government's efforts to hold accountable those whose conduct may put patients at risk."
多布斯在其宣誓书中写道:“为外国市场生产的药品,根据美国法律几乎总是被视为未获批准和标签错误的药物,无论是假冒产品,还是即使由生产美国销售版本的同一制造商生产。”
"Pharmaceuticals manufactured for foreign markets are almost always considered unapproved and misbranded drugs under U.S. law, whether counterfeit or even if made by the same manufacturer that produced the version sold in the United States," Dobbs wrote in his affidavit.